Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1983]
News [3212]
Articles [134]
Editorials [3]
Conferences [121]
elearning [18]
First two CAR-T cell medicines recommended for approval in the European Union
First two CAR-T cell medicines recommended for approval in the European Union
New drugs are improving survival times for patients with aggressive type of blood cancer
New drugs are improving survival times for patients with aggressive type of blood cancer
New regulatory axis revealed for the cancer relevant matrix metalloprotease MMP14
New regulatory axis revealed for the cancer relevant matrix metalloprotease MMP14
T-cell leukaemia: Cancer cells take advantage of 'survival protein'
T-cell leukaemia: Cancer cells take advantage of 'survival protein'
Research team discovers drug compound that stops cancer cells from spreading
Research team discovers drug compound that stops cancer cells from spreading
European Commission grants approval to blinatumomab for ALL
European Commission grants approval to blinatumomab for ALL
EHA 23: Quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML
EHA 23: Quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML
EHA 23: JAK inhibitors associated with aggressive lymphoma
EHA 23: JAK inhibitors associated with aggressive lymphoma
Researchers map the genome of testicular cancer
Researchers map the genome of testicular cancer
Modern blood cancer treatments require new approach for monitoring, reporting side effects
Modern blood cancer treatments require new approach for monitoring, reporting side effects

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation